Evidence map›Paper›PMID 16868798›Full record

ReviewJournal of gastroenterology2006

Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification.

Hidekazu Suzuki, Toshihiro Nishizawa, Toshifumi Hibi

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Journal of gastroenterology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01591174 (Evaluation of Liquid Gastric Emptying and Plasma Ghrelin in Children With Functional Dyspepsia), which is not on this map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01591174 completednot on this mapstarted 2012, after this paper: background citation

Evaluation of Liquid Gastric Emptying and Plasma Ghrelin in Children With Functional Dyspepsia

TypeobservationalSponsorChildren's Mercy Hospital Kansas CityRan2012 to 2016Enrolled30ConditionsFunctional Dyspepsia
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Itopride therapy for functional dyspepsia: a meta-analysis.World journal of gastroenterology · 2012
    Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Helicobacter pylori infection in functional dyspepsia.Nature reviews. Gastroenterology & hepatology · 2013
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Proton-pump inhibitors for the treatment of functional dyspepsia.Therapeutic advances in gastroenterology · 2011
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Ghrelin and functional dyspepsia.International journal of peptides · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Hidekazu SuzukiDepartment of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Tokyo, 160-8582, Japan.
Toshihiro Nishizawa
Toshifumi Hibi
Keio University · JPKeio University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although placebo response rates in clinical trials for functional dyspepsia (FD) are more than 30%, a recent meta-analysis based on randomized controlled trials (RCTs) showed that antisecretory drugs were more or less superior to placebos. On the other hand, large-scale RCTs on the efficacy of treatment with prokinetics on FD are still needed. Indications for antibiotic eradication therapy for Helicobacter pylori-positive FD are still controversial, but there seems to be a small but significant therapeutic gain achieved with H. pylori eradication. Since preprandial and postprandial symptomatic disturbances are very important targets for FD treatment, ghrelin, a novel appetite-promoting gastrointestinal peptide that also promotes gastric motility or basal acid secretion can be expected to be a therapeutic target. In the recently published Rome III classification, FD is redefined for patients with symptoms thought to originate from the gastroduodenal region, specifically epigastric pain or burning, postprandial fullness, or early satiation, and it is divided into the subcategories postprandial distress syndrome and epigastric pain syndrome. These new criteria are of value in clinical practice, for epidemiological, pathophysiological, and clinical research, and for the development of new therapeutic strategies.

Indexed as

Clinical Trials as TopicDyspepsiaHelicobacter InfectionsHelicobacter pyloriHumans

Identifiers

PMID16868798
OpenAlexW2068883063

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.